Louisiana State Employees Retirement System Takes $2.94 Million Position in Krystal Biotech, Inc. $KRYS

Louisiana State Employees Retirement System bought a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) in the 1st quarter, HoldingsChannel.com reports. The firm bought 11,400 shares of the company’s stock, valued at approximately $2,945,000.

A number of other hedge funds have also made changes to their positions in KRYS. Greenline Wealth Management LLC bought a new stake in shares of Krystal Biotech in the fourth quarter worth $34,000. Sound Income Strategies LLC boosted its stake in Krystal Biotech by 1,270.0% during the 4th quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock valued at $34,000 after acquiring an additional 127 shares during the last quarter. UMB Bank n.a. boosted its stake in Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after acquiring an additional 37 shares during the last quarter. Global Retirement Partners LLC grew its holdings in Krystal Biotech by 788.9% during the 4th quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock worth $39,000 after acquiring an additional 142 shares in the last quarter. Finally, Danske Bank A S acquired a new position in Krystal Biotech during the 3rd quarter worth $35,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on KRYS shares. Wall Street Zen lowered shares of Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Citigroup lifted their price target on Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. HC Wainwright lifted their price target on shares of Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a report on Tuesday, June 16th. TD Cowen boosted their price objective on Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Finally, Wolfe Research began coverage on shares of Krystal Biotech in a research report on Friday, March 27th. They issued a “peer perform” rating for the company. Ten investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $340.56.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS opened at $372.25 on Monday. The company’s fifty day moving average is $304.72 and its two-hundred day moving average is $276.99. The company has a market cap of $10.97 billion, a P/E ratio of 49.77 and a beta of 0.53. Krystal Biotech, Inc. has a 12-month low of $130.50 and a 12-month high of $376.28.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. The firm had revenue of $116.36 million during the quarter, compared to analysts’ expectations of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. Equities research analysts anticipate that Krystal Biotech, Inc. will post 7.66 earnings per share for the current year.

Insiders Place Their Bets

In other Krystal Biotech news, EVP John Charles Thomas sold 1,000 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the completion of the transaction, the executive vice president owned 1,000 shares in the company, valued at $347,270. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the sale, the insider owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. This trade represents a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 26,642 shares of company stock valued at $8,243,923 over the last 90 days. 13.10% of the stock is currently owned by corporate insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.